遗传 ›› 2006, Vol. 28 ›› Issue (9): 1061-1066.

• 研究报告 • 上一篇    下一篇

宫颈癌患者血浆和组织中FHIT基因5′端CpG岛甲基化状态的研究

任晨春1,2, 苗绪红2, 杨 斌2, 赵 磊2, 孙 蕊2, 宋文芹2   

  1. 1. 天津市中心妇产科医院遗传室, 天津300052; 2. 南开大学生命科学院, 天津 300074
  • 收稿日期:2005-11-07 修回日期:2006-04-27 出版日期:2006-09-01 发布日期:2006-09-01
  • 通讯作者: 宋文芹

Methylation Status of the 5′ CpG Islands in FHIT Gene in the Plasma and Tissues of Cervical Cancer Patients

REN Chen-Chun1,2, MIAO Xu-Hong2, YANG Bin2, ZHAO Lei2, SUN Rui2, SONG Wen-Qin2

  

  1. 1. Department of Genetics, Central Hospital of Gynecology and Obstetrics, Tianjin 300052,China; 2. College of Life Sciences,
    Nankai University, Tianjin 300074, China
  • Received:2005-11-07 Revised:2006-04-27 Online:2006-09-01 Published:2006-09-01
  • Contact: SONG Wen-Qin

摘要: 为了检测宫颈癌患者血浆和组织中FHIT基因5′端CpG岛甲基化状态, 以找到无创伤性诊断宫颈癌的新指标, 选取151例宫颈癌患者的血浆和30例患者的宫颈癌组织为研究对象,用MSP的方法检测FHIT基因5′端CpG岛甲基化状态, 并对MSP产物进行克隆和测序。结果在宫颈癌患者血浆和组织中, FHIT基因5′端CpG岛甲基化率为30.46%和53.33%, 血浆和组织的总体符合率为80%。而对照中均未检测到甲基化状态。随着患者临床分期和组织学分级的增加, FHIT基因甲基化的检出率也在逐渐的增加。表明宫颈癌患者的血浆和肿瘤组织中FHIT基因5′端CpG岛甲基化的发生是高频事件, 使用FHIT基因作为标记可以对宫颈癌患者进行无创伤诊断和预后的评估。

关键词: 宫颈癌, 甲基化状态, FHIT基因, 组织, 血浆

Abstract: To evaluate the methylation status of the 5′ CpG islands in FHIT gene using plasma and tissue samples from cervical cancer patients and find a novel marker for non-invasive diagnosis of cervical cancer, methylation-specific PCR (MSP) was employed to examine CpG island methylation in FHIT gene in 151 pretreatment plasma samples and 30 tumor tissue samples obtained from cervical cancer patients. MSP product was cloned and sequenced directly. CpG island methylation of FHIT was detected in 31.13% of the plasma samples, and in 53.33% of the tissue samples. The total concordant rate of methylation status between plasma and tissue samples in FHIT gene was 80.00%. We found a strong positive correlation between FHIT methylation in the plasma and the clinical stage and histological grade of the tumor. The data showed that CpG island methylation of the FHIT gene is prevalent in the plasma and tissue samples from cervical cancer patients. FHIT detection may be used as a non-invasive marker for diagnosis of cervical cancer and prognostic treatment evaluation.

中图分类号: